celecoxib has been researched along with epirubicin in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (14.29) | 29.6817 |
| 2010's | 11 (78.57) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Benfenati, E; Raska, I; Toropov, AA; Toropova, AP | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chow, LW; Loo, WT; Lui, EL; Toi, M; Wai, CC; Zhu, L | 1 |
| Chow, LW; Toi, M; Ueno, T | 1 |
| Bidard, FC; Brain, E; de Cremoux, P; Delaloge, S; Giachetti, S; Marty, M; Mathiot, C; Pierga, JY | 1 |
| Bertheau, P; Brain, E; Delaloge, S; Espié, M; Guinebretière, JM; Marty, M; Mathieu, MC; Pierga, JY; Savignoni, A; Sigal-Zafrani, B; Spielmann, M | 1 |
| Chow, LW; Glück, S; Im, SA; Lee, MH; Ng, TY; Toi, M; Tung, SY; Yip, AY | 1 |
| Ju, RJ; Li, XT; Li, XY; Liu, L; Lu, WL; Shi, JF; Sun, MG; Zeng, F; Zhang, CX; Zhao, WY; Zhou, J | 1 |
| Hu, YJ; Ju, RJ; Liu, L; Lu, WL; Mu, LM; Wu, JS; Xie, HJ; Yan, Y; Zeng, F; Zhao, Y | 1 |
| Asselain, B; Berger, F; Bertheau, P; Brain, E; Delaloge, S; Espié, M; Giacchetti, S; Guinebretière, JM; Hamy, AS; Lerebours, F; Marty, M; Mathieu, MC; Mazouni, C; Pierga, JY; Reyal, F; Saghatchian, M; Sigal-Zafrani, B; Tembo, O | 1 |
| Chan, HH; Chang, YC; Chen, YA; Chu, TH; Hu, TH; Huang, SC; Ma, YL; Tai, MH; Wang, EM; Wen, ZH; Weng, WT; Wu, DC; Wu, JC | 1 |
| Baez-Diaz, L; Bandos, H; Brufsky, AM; Carolla, RL; Fehrenbacher, L; Geyer, CE; Hamm, JT; Jacobs, SA; Julian, TB; Mamounas, EP; Paterson, AHG; Polikoff, J; Provencher, L; Rastogi, P; Robidoux, A; Swain, SM; Ward, PJ; Wolmark, N | 1 |
1 review(s) available for celecoxib and epirubicin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
5 trial(s) available for celecoxib and epirubicin
| Article | Year |
|---|---|
Increases in circulating VEGF levels during COX-2 inhibitor treatment in breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Celecoxib; Cyclooxygenase 2 Inhibitors; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Neoadjuvant Therapy; Pyrazoles; Sulfonamides; Vascular Endothelial Growth Factor A | 2006 |
Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Celecoxib; Cell Separation; Cyclophosphamide; Docetaxel; Early Detection of Cancer; Epirubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplastic Cells, Circulating; Pyrazoles; Sulfonamides; Survival Analysis; Taxoids; Time Factors; Trastuzumab; Young Adult | 2010 |
A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients.
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Celecoxib; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; France; Humans; In Situ Hybridization, Fluorescence; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Pyrazoles; Receptor, ErbB-2; Sulfonamides; Taxoids; Therapeutics; Time Factors; Trastuzumab | 2010 |
Concurrent celecoxib with 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel for stages II - III invasive breast cancer: the OOTR-N001 study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Celecoxib; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Phenobarbital; Prospective Studies; Pyrazoles; Receptor, ErbB-2; Sulfonamides; Taxoids | 2013 |
Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Celecoxib; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Female; Humans; Middle Aged; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2017 |
8 other study(ies) available for celecoxib and epirubicin
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Study of COX-2, Ki67, and p53 expression to predict effectiveness of 5-flurouracil, epirubicin and cyclophosphamide with celecoxib treatment in breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Celecoxib; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Genes, p53; Humans; Immunohistochemistry; Ki-67 Antigen; Middle Aged; Pyrazoles; Sulfonamides | 2005 |
Liposomes, modified with PTD(HIV-1) peptide, containing epirubicin and celecoxib, to target vasculogenic mimicry channels in invasive breast cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast; Breast Neoplasms; Celecoxib; Cell Line, Tumor; Drug Delivery Systems; Epirubicin; Female; HIV-1; Humans; Liposomes; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Neovascularization, Pathologic; Peptides; Phosphatidylethanolamines; Polyethylene Glycols; Pyrazoles; Sulfonamides | 2014 |
Destruction of vasculogenic mimicry channels by targeting epirubicin plus celecoxib liposomes in treatment of brain glioma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blood-Brain Barrier; Brain Neoplasms; Caspase 8; Celecoxib; Cell Line, Tumor; Epirubicin; Glioma; Humans; Liposomes; Male; Mice, Nude; Neoplasm Recurrence, Local | 2016 |
Celecoxib enhances the therapeutic efficacy of epirubicin for Novikoff hepatoma in rats.
Topics: Animals; Antibiotics, Antineoplastic; Apoptosis; Biomarkers; Carcinoma, Hepatocellular; Celecoxib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Epirubicin; Humans; Immunomodulation; Liver Neoplasms, Experimental; Rats; Topoisomerase II Inhibitors; Treatment Outcome; Xenograft Model Antitumor Assays | 2018 |
Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology).
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Celecoxib; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Mastectomy | 2022 |